PROF

Business Context and Reporting Period

Company: Profound Medical Corp. (Profound)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Profound is a commercial-stage medical device company developing customizable, incision-free therapeutic systems for the ablation of diseased tissue. Its lead product, the TULSA-PRO system, utilizes real-time MRI and thermal ultrasound for prostate tissue ablation (cancer and BPH). The Sonalleve system treats uterine fibroids, bone metastases, and osteoid osteoma. The company operates primarily in the United States, EU, and Asia.

Key Financial Metrics

Note: All financial figures are in thousands of USD unless otherwise noted.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 48% to $10.68 million, driven by higher recurring revenue and capital sales in the U.S. market. U.S. revenue now accounts for approximately 78% of total revenue (up from 71% in 2023).
• Expense Increases: Operating expenses rose 22% to $40.1 million. Research and Development (R&D) increased 18% due to headcount growth and the CAPTAIN trial. Selling, General, and Administrative (SG&A) expenses increased 25% due to sales force expansion, commissions, and marketing campaigns.
• Financing Activity: The company raised significant capital through two public offerings and a private placement in 2024, resulting in net proceeds of approximately $57.2 million. This increased cash holdings by $28.7 million year-over-year.
• Debt Restructuring: While the company repaid $2.56 million of long-term debt principal during the year, it entered into an amended and restated credit agreement with CIBC in March 2025 (subsequent event) to replace the term loan with a revolving line of credit.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Commercialization: Management expects to fund operations for at least the next 12 months using existing cash and product sales. The focus remains on expanding the U.S. sales force and commercializing the TULSA-PRO system.
• Reimbursement: A significant milestone was achieved with the Centers for Medicare and Medicaid Services (CMS) establishing Category 1 CPT codes for the TULSA procedure effective January 1, 2025, with payment rates finalized in November 2024.
• Strategic Partnerships: In December 2024, Profound announced a co-sales and co-marketing agreement with Siemens Healthineers for the TULSA-PRO and Free.Max MRI systems.

Risks and Contingencies

• Internal Control Material Weakness: The company identified a material weakness in internal controls over financial reporting related to revenue recognition (ASC 606) and contract review. This resulted in audit adjustments prior to the issuance of financial statements. Remediation is ongoing.
• Debt Covenants: The company previously breached a revenue covenant in Q1 2024 but obtained a waiver. Current covenants require unrestricted cash to exceed specific thresholds or negative EBITDA. Management notes potential for future breaches due to revenue volatility.
• Regulatory and Trade: New U.S. tariffs on imports from Canada (25%) and China (10%) effective February 2025 may materially impact costs, as manufacturing occurs in Canada and components are sourced globally.
• Capital Needs: The company has a history of operating losses and an accumulated deficit of $245.2 million. Continued profitability is not guaranteed, and additional financing may be required.

Investor Verification Checklist

• Revenue Recognition Controls: Verify the progress of remediation for the material weakness in revenue recognition controls and assess the risk of future restatements.
• Cash Runway: Confirm the sufficiency of the $54.9 million cash balance against the burn rate, considering the increased SG&A and R&D spend.
• Debt Covenant Compliance: Monitor monthly compliance with the CIBC Credit Agreement covenants, specifically the unrestricted cash and recurring revenue thresholds.
• Tariff Impact: Assess the financial impact of the new U.S. tariffs on Canadian and Chinese imports on the cost of goods sold and gross margins.
• CMS Reimbursement Uptake: Track the actual utilization of the new TULSA CPT codes by providers to validate the revenue growth assumptions for 2025.